Clinical Trial Update: Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating whether adding empagliflozin, an SGLT2 inhibitor, can mitigate metabolic disturbances associated with olanzapine in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Schizophrenia

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Tanta University | Conditions: Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics | Phase 3 | Status: RECRUITING